



ASX Announcement and Media Release

22 November 2011

SciGen Ltd

Disposal of SciGen's interest in its Manufacturing facility in Israel and Hepatitis B Vaccine Licence

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) has concluded Agreements for the sale of SciGen's 100% interest in SciGen (IL) Ltd (“**SIL**”) (**SIL Shares**) and for the assignment of all of SciGen's licensing rights for the manufacture and sale of Hepatitis B Vaccine (“**HBV Licence**”) to FDS Pharma LLP for a cash consideration of US\$ 2 million and a royalty income of 5% on future global sales. The sale is conditional upon the fulfilment of conditions precedent, which include the consent of the administrative and regulatory bodies of the State of Israel.

Both the SIL Shares and the HBV Licence are disclosed in the accounts as “Assets held for resale” and as of 30 September 2011 is valued at US\$ 9.1 million after provision for impairment. The Directors expect that the transaction will be closed before the end of this calendar year and the loss will be reflected in the accounts for the current financial year. Disposal of the SIL Shares and the HBV Licence will have positive impact on SciGen's cash flow moving forward.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical

development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India, Israel and Philippines, distribution channels in China, Hong Kong, India, Indonesia, Malaysia, Pakistan and Thailand, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638